CERS

Cerus Corporation (CERS) is a pioneering biomedical products firm focused on enhancing blood safety through its proprietary INTERCEPT Blood System, designed to inactivate harmful pathogens in blood components. Headquartered in Concord, California, Cerus leverages advanced technologies to meet the critical needs of transfusion medicine, significantly improving patient safety. With a robust and expanding product portfolio, the company is strategically positioned to capitalize on the increasing global demand for safe blood products, while actively advancing blood safety protocols and contributing to vital public health initiatives.